top of page

業績（2019年）

Publications

  1. Fujiwara S, Hattori N, Matsui T, Nakata A, Sasaki Y, Shimada S, Murai S, Abe M, Baba Y, Watanuki M, Kawaguchi Y, Arai N, Kabasawa N, Tsukamoto H, Uto Y, Yanagisawa K, Harada H, Nakamaki T. Refined Disease Risk Index for Hematological Malignancies, Including Rare Disorders, After Allogeneic Stem Cell Transplantation. Transplant Proc. 2019 Dec;51(10):3437-3443. PMID: 31733801

  2. Baba Y, Saito B, Shimada S, Sasaki Y, Murai S, Abe M, Fujiwara S, Arai N, Kawaguchi Y, Kabasawa N, Tsukamoto H, Uto Y, Yanagisawa K, Hattori N, Harada H, Nakamaki T. Development of cardiac tamponade and emergence of arrhythmia during chemotherapy for diffuse large B-cell lymphoma. Rinsho Ketsueki. 2019; 60(6): 577-581. Japanese. PMID: 31281147

  3. Hattori N, Nakamaki T. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Int J Mol Sci. 2019; 26; 20(9):2057. PMID: 31027331

  4. Arai N, Homma M, Abe M, Baba Y, Murai S, Watanuki M, Kawaguchi Y, Fujiwara S, Kabasawa N, Tsukamoto H, Uto Y, Ariizumi H, Yanagisawa K, Hattori N, Saito B, Shiozawa E, Harada H, Yamochi-Onizuka T, Nakamaki T, Takimoto M. Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia. Int J Hematol. 2019; 109(5): 539-544. PMID: 30847774

  5. Hattori N, Kawaguchi Y, Sasaki Y, Shimada S, Murai S, Abe M, Baba Y, Watanuki M, Fujiwara S, Arai N, Kabasawa N, Tsukamoto H, Uto Y, Yanagisawa K, Saito B, Harada H, Nakamaki T. Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2019;25(5):861-867. PMID: 30639819

  6. Lao ZT, Ding LW, An O, Hattori N, Sun QY, Tan KT, Mayakonda A, Chuan WG, Madan V, Lin DC, Yang H, Koeffler HP. Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias. Haematologica. 2019;104(5): e200-e203. PMID: 30514800

  7. Nishio Y, Sakai H, Saiki Y, Uchida A, Uemura Y, Matsunawa M, Isobe Y, Kato M, Tomita N, Miura I. Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele.Int J Hematol. 2019 May;109(5):572-577. PMID: 30887274

  8. Aizawa R, Yamada A, Seki T, Tanaka J, Nagahama R, Ikehata M, Kato T, Sakashita A, Ogata H, Chikazu D, Maki K, Mishima K, Yamamoto M, Kamijo R.Cdc42 regulates cranial suture morphogenesis and ossification.Biochem Biophys Res Commun. 2019 Apr 30;512(2):145-149. PMID: 30853186

  9. Kato T, Yamada A, Sasa K, Yoshimura K, Morimura N, Ogata H, Sakashita A, Kamijo R. Nephronectin Expression is Inhibited by Inorganic Phosphate in Osteoblasts. Calcif Tissue Int. 2019 Feb;104(2):201-206. PMID: 30341591

  10. Nishio Y, Sakai H, Saiki Y, Uchida A, Uemura Y, Matsunawa M, Isobe Y, Kato M, Tomita N, Miura I. Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele. Int J Hematol. 2019 May;109(5):572-577. PMID: 30887274

  11. Yogo T, Tsukada N, Nashimoto J, Uto Y, Sato K, Miyazaki K, Ogura M, Yoshiki Y, Abe Y, Okazuka K, Ishida T, Suzuki K. Efficacy of plerixafor in autologous peripheral blood stem cell collection. Rinsho Ketsueki. 2019;60(3):165-170. PMID: 31068511 Japanese

  12. Sato K, Tsukada N, Nashimoto J, Uto Y, Miyazaki K, Ogura M, Yoshiki Y, Abe Y, Okazuka K, Ishida T, Suzuki K.  Elotuzumab treatment for a multiple myeloma patient relapsing after allogenic stem cell transplantation. Rinsho Ketsueki.  2019;60(12):1635-1640. PMID: 31902813 Japanese

  13. Yogo T, Okazuka K, Nashimoto J, Uto Y, Sato K, Miyazaki K, Ogura M, Yoshiki Y, Abe Y, Tsukada N, Ishida T, Suzuki K. Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis.  Int J Hematol. 2019 Oct;110(4):431-437. PMID: 31236823

bottom of page